Niagen Bioscience Stock Rating Reiterated by Canaccord Amid Drug Launch

Canaccord Genuity has reiterated its buy rating on Niagen Bioscience following the launch of a new drug. This move indicates confidence in the company's growth prospects and market strategy. Specific financial metrics related to the launch, such as expected revenue increases or projected market share, were not disclosed. For investors, this suggests potential upside in the stock as the company capitalizes on its latest product offering.